Cancer Stem Cell News Volume 5.01 | Jan 13 2016

MiR-215 Is Induced Post-Transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B
The authors report that hypoxia-induced miR-215 is vital for reprograming glioma-initiating cells to fit the hypoxic microenvironment via suppressing the expression of an epigenetic regulator KDM1B and modulating activities of multiple pathways. [Cancer Cell] Abstract | Graphical Abstract

Interactions between Adipocytes and Breast Cancer Cells Stimulate Cytokine Production and Drive Src/Sox2/miR-302b–Mediated Malignant Progression
Investigators examined the effects of coculturing human-derived adipocytes with established and primary breast cancer cells on tumorigenic potential. Prolonged culture of cancer cells with adipocytes or cytokines increased the proportion of mammosphere-forming cells and of cells expressing stem-like markers in vitro. [Cancer Res] Abstract | Full Article

Preferential Expression of Functional IL-17R in Glioma Stem Cells: Potential Role in Self-Renewal
Researchers explored the potential direct impact of IL-17−IL-17R interaction in gliomas. Immunohistochemistry and flow cytometry analysis of 12 tumor samples obtained from patients with high grade gliomas revealed that a considerable population of cells in all malignant gliomas expressed IL-17RA, with remarkable co-expression of the glioma stem cell markers CD133, Nestin, and Sox2. [Oncotarget] Full Article

A Disintegrin and Metalloproteinase Domain 17 Regulates Colorectal Cancer Stem Cells and Chemosensitivity Via Notch1 Signaling
Investigators determined whether A disintegrin and metalloproteinase domain 17 regulates the cancer stem cell phenotype in colorectal cancer and elucidated the downstream signaling mechanism that mediates cancer stem-ness. [Stem Cells Transl Med] Abstract | Full Article

Low Adherent Cancer Cell Subpopulations Are Enriched in Tumorigenic and Metastatic Epithelial-to-Mesenchymal Transition-Induced Cancer Stem-Like Cells
Investigators demonstrated that trypsin-sensitive breast and colon cancer cells subpopulations show increased ALDH activity, higher ability to exclude Hoechst 33342, enlarged proportion of cells with a cancer stem-like cell phenotype and are enriched in sphere- and colony-forming cells in vitro. [Sci Rep] Full Article

miR-137 Regulates the Tumorigenicity of Colon Cancer Stem Cells Through the Inhibition of DCLK1
A PCR-based microRNA (miRNA) profiling analysis of normal colon stem cell (NCSCs) and colon cancer stem cell (CSCs) identified miRNAs which regulate colon CSC properties. miRNA-137 (miR-137) expression was downregulated in the colon CSCs compared to NCSCs, while doublecortin-like kinase 1 (DCLK1) mRNA was highly expressed in the colon CSCs but low in the NCSCs. [Mol Cancer Res] Abstract

Mucin 1-Mediated Chemo-Resistance in Lung Cancer Cells
Researchers demonstrated that non-small cell lung cancers survive paclitaxel (PTX) treatment. The proportion of the cancer stem cell marker, aldehyde dehydrogenase-positive cells, and epithelial–mesenchymal transition signaling protein levels were elevated in PTX-resistant A549 cells. [Oncogenesis] Full Article

Dnajb8, a Member of the Heat Shock Protein 40 Family Has a Role in the Tumor Initiation and Resistance to Docetaxel but Is Dispensable for Stress Response
Scientists established Dnajb8 knockout renal cell carcinoma (RCC) line cells and analyzed the cells to confirm the function of Dnajb8 in RCC cancer stem-like cells/cancer-initiating cells. [PLoS One] Full Article

Visit our reviews page to see a complete list of reviews in the Cancer Stem Cell research field.

From our sponsor: Culturing hematopoietic stem and progenitor cells? Download the technical bulletin.

Historic National Coalition Formed to Accelerate Next Generation Immunotherapy in Cancer
Leaders from large pharma including Celgene and Amgen, biotech including NantWorks, NantKwest, Etubics, Altor Bioscience, and Precision Biologics, major academic cancer centers and community oncologists announced the launch of The National Immunotherapy Coalition, a historic alliance—in collaboration with Independence Blue Cross—with a singular focus: accelerating the potential of combination immunotherapies as the next generation standard of care in patients with cancer. [Business Wire] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the Cancer Stem Cell community.

NEW Postdoctoral Scientist – Follicular Lymphoma (Herbert Irving Comprehensive Cancer Center)

Postdoctoral Researcher – Prostate Cancer Biology (Roswell Park Cancer Institute)

Postdoctoral Fellow – Cell and Molecular Biology of Leukemia (Virginia Commonwealth University)

Postdoctoral Fellow – Cancer Stem Cell Biology (Cleveland Clinic)

Postdoctoral Fellow – Cancer and Neurodegenerative Disease (University of Pennsylvania)

Postdoctoral Position – Immunotherapy Targeting Cancer Stem Cells (Ecole Polytechnique Fédérale de Lausanne)

Director – Cancer Center (The University of Hawai‘i Cancer Center)

Assistant Member – Radioimmunotherapy (Fred Hutchinson Cancer Research Center)

Faculty Positions – Cancer Pharmacology (Northwestern University)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.